Exelixis | EXEL - Selling And Administration Expenses


Exelixis reported $139.6M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 160.79M 14.06M Mar/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Amgen USD 1.58B 354M Mar/2026
AstraZeneca USD 5.06B 455M Mar/2026
Bayer EUR 3.7B 356M Mar/2026
BioMarin Pharmaceutical USD 258.28M 63.92M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cytokinetics USD 104.9M 13.17M Mar/2026
Eisai JPY 119.54B 7.82B Mar/2026
Eli Lilly USD 2.93B 198M Mar/2026
Esperion Therapeutics USD 39.42M 456K Dec/2025
Exelixis USD 139.6M 16.58M Mar/2026
Genmab DKK 208M 60M Dec/2025
Glaxosmithkline GBP 3.56B 650.29M Dec/2025
Incyte USD 328.1M 62.31M Mar/2026
Ionis Pharmaceuticals USD 151M 21M Mar/2026
MacroGenics USD 7.94M 1.96M Dec/2025
Merck USD 2.67B 180M Mar/2026
Moderna USD 173M 135M Mar/2026
Nektar Therapeutics USD 10.17M 10.17M Dec/2025
Neurocrine Biosciences USD 318.5M 16.7M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
Puma Biotechnology USD 16.82M 8.15M Sep/2024
Sanofi EUR 2.75B 455M Dec/2025
Takeda JPY 292B 9.21B Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Xencor USD 82.12M 65.08M Mar/2026